赛诺菲抗癌药Zaltrap 前列腺癌III期研究败北

2012-04-16 potato 生物谷

2012年4月5日，赛诺菲（Sanofi）公司和Regeneron制药公司今天宣布，其合作开发的抗癌药物Zaltrap（也称aflibercept）在一项关于前列腺癌治疗的III期研究中未达到预期目标，不过，美国当局正在审查该药用于结肠癌的治疗。去年12月，Regeneron公司称，赛诺菲公司已撤回有关抗癌药Zalrap的上市审批申请，并计划在今年年初重新提交。 "该项III期研究未达到改善

2012年4月5日，赛诺菲（Sanofi）公司和Regeneron制药公司今天宣布，其合作开发的抗癌药物Zaltrap（也称aflibercept）在一项关于前列腺癌治疗的III期研究中未达到预期目标，不过，美国当局正在审查该药用于结肠癌的治疗。

去年12月，Regeneron公司称，赛诺菲公司已撤回有关抗癌药Zalrap的上市审批申请，并计划在今年年初重新提交。

"该项III期研究未达到改善前列腺癌患者整体存活率的预期目标，"赛诺菲公司称。

不过，美国FDA已授予Zaltrap用于结肠癌治疗的优先审查地位（priority review），赛诺菲公司在周四发表的声明中补充道。FDA计划在8月4日作出决定。优先审查将减少FDA审查药物申请的时间，从10个月减少至6个月。

一种药物，如果初步显示其对一些无足够疗法的疾病具有治疗的潜力，或与市售药物相比具有显着的改善作用，则该药物对这些疾病的治疗将被授予优先审查地位，赛诺菲公司称。

"赛诺菲公司和Regeneron公司将继续致力于Zaltrap的开发，"赛诺菲公司肿瘤学主任Dabasish Roychowdhury在声明中称。（生物谷bioon.com）

编译自：Routers
http://www.reuters.com/article/2012/04/05/us-sanofi-regeneron-idUSBRE83406G20120405

相关阅读

PK辩论台：前列腺癌必须治疗吗？

“三重打击”药物Galeterone—晚期前列腺癌患者的新希望

强生（J&J）前列腺癌药物Zytiga新研究中达预期目标

PLoS ONE：晚期前列腺癌治疗的新选择

前列腺癌发病机制研究“973计划”项目在上海启动

NIH：并非所有前列腺癌都要急治

2011年研发投入最大的15家生物技术公司

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1915755, encodeId=75191915e5531, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 25 07:51:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656502, encodeId=e8b6165650223, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Aug 24 04:51:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005361, encodeId=83702005361c2, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 09 12:51:00 CST 2012, time=2012-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021309, encodeId=f3132021309e9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Jul 28 03:51:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860941, encodeId=25e9186094102, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Mar 21 10:51:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314568, encodeId=d7dd1314568a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594312, encodeId=838e1594312de, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2013-01-25 juliusluan78

#III#

67 0
[GetPortalCommentsPageByObjectIdResponse(id=1915755, encodeId=75191915e5531, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 25 07:51:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656502, encodeId=e8b6165650223, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Aug 24 04:51:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005361, encodeId=83702005361c2, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 09 12:51:00 CST 2012, time=2012-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021309, encodeId=f3132021309e9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Jul 28 03:51:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860941, encodeId=25e9186094102, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Mar 21 10:51:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314568, encodeId=d7dd1314568a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594312, encodeId=838e1594312de, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-08-24 bsmagic9140

#TRA#

73 0
[GetPortalCommentsPageByObjectIdResponse(id=1915755, encodeId=75191915e5531, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 25 07:51:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656502, encodeId=e8b6165650223, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Aug 24 04:51:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005361, encodeId=83702005361c2, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 09 12:51:00 CST 2012, time=2012-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021309, encodeId=f3132021309e9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Jul 28 03:51:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860941, encodeId=25e9186094102, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Mar 21 10:51:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314568, encodeId=d7dd1314568a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594312, encodeId=838e1594312de, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-06-09 xue8602

#TRAP#

91 0
[GetPortalCommentsPageByObjectIdResponse(id=1915755, encodeId=75191915e5531, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 25 07:51:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656502, encodeId=e8b6165650223, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Aug 24 04:51:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005361, encodeId=83702005361c2, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 09 12:51:00 CST 2012, time=2012-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021309, encodeId=f3132021309e9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Jul 28 03:51:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860941, encodeId=25e9186094102, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Mar 21 10:51:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314568, encodeId=d7dd1314568a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594312, encodeId=838e1594312de, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-07-28 HinsMax

#III期研究#

69 0
[GetPortalCommentsPageByObjectIdResponse(id=1915755, encodeId=75191915e5531, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 25 07:51:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656502, encodeId=e8b6165650223, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Aug 24 04:51:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005361, encodeId=83702005361c2, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 09 12:51:00 CST 2012, time=2012-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021309, encodeId=f3132021309e9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Jul 28 03:51:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860941, encodeId=25e9186094102, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Mar 21 10:51:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314568, encodeId=d7dd1314568a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594312, encodeId=838e1594312de, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2013-03-21 shizhenshan

#ALT#

79 0
[GetPortalCommentsPageByObjectIdResponse(id=1915755, encodeId=75191915e5531, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 25 07:51:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656502, encodeId=e8b6165650223, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Aug 24 04:51:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005361, encodeId=83702005361c2, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 09 12:51:00 CST 2012, time=2012-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021309, encodeId=f3132021309e9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Jul 28 03:51:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860941, encodeId=25e9186094102, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Mar 21 10:51:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314568, encodeId=d7dd1314568a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594312, encodeId=838e1594312de, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-04-18 sunylz

#抗癌药#

88 0
[GetPortalCommentsPageByObjectIdResponse(id=1915755, encodeId=75191915e5531, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 25 07:51:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656502, encodeId=e8b6165650223, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Aug 24 04:51:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005361, encodeId=83702005361c2, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 09 12:51:00 CST 2012, time=2012-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021309, encodeId=f3132021309e9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Jul 28 03:51:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860941, encodeId=25e9186094102, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Mar 21 10:51:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314568, encodeId=d7dd1314568a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594312, encodeId=838e1594312de, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-04-18 智智灵药

#III期#

68 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药械

赛诺菲抗癌药Zaltrap 前列腺癌III期研究败北

相关资讯

科室

工具

服务